It was another busy week for Australia’s top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone:
Credit Corp Group Ltd (ASX: CCP)
According to a note out of Morgans, its analysts have retained their buy rating on this debt collector’s shares with a reduced price target of $19.35. This follows the release of Credit Corp’s first-half results, which revealed profits that were 10% short of expectations. While disappointing, Morgans feels the selloff that followed, which dragged its shares 17% lower, was overdone and has created a buying opportunity for investors. The broker highlights that at just 7x estimated FY 2027 earnings, Credit Corp’s valuation is undemanding. This is especially the case given that management has reiterated its guidance for FY 2026. The Credit Corp share price ended the week at $11.25.
NextDC Ltd (ASX: NXT)
A note out of Macquarie reveals that its analysts have retained their outperform rating and $22.30 price target on this data centre operator’s shares. Macquarie points out that Singtel and private equity firm KKR have acquired Singapore-based ST Telemedia Global Data Centres for approximately S$13.8 billion (A$15.5 billion). It estimates that this represents a 20x EV/EBITDA multiple, which is significantly greater than its 14.8x estimate for NextDC shares. In light of this, the broker continues to believe that NextDC shares are significantly undervalued at current levels, making now an opportune time for investors to open positions. The NextDC share price was fetching $12.71 at Friday’s close.
ResMed Inc. (ASX: RMD)
Another note out of Morgans reveals that its analysts have upgraded this sleep disorder treatment company’s shares to a buy rating with a $47.73 price target. Morgans was pleased with ResMed’s performance in the second quarter of FY 2026. The broker highlights that its result was a beat across the board, with double-digit revenue and earnings growth, further gross margin expansion, and solid cash generation. In response to ResMed’s operating leverage, the broker has lifted its earnings estimates and valuation slightly. And with its shares down materially from recent highs, Morgans thinks now is a good time to invest. The ResMed share price ended the week at $37.92.
The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.
Should you invest $1,000 in Credit Corp Group Limited right now?
Before you buy Credit Corp Group Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Credit Corp Group Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- I would invest $50,000 in these ASX 200 shares if I were aiming to beat the market in 2026
- How could I turn $500 a month into $50,000 with ASX shares?
- Passive income: How much do you need to invest to make $500 per month?
- What the stronger Australian dollar means for your shares
- Brokers name 3 ASX shares to buy today
Motley Fool contributor James Mickleboro has positions in Nextdc and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.